PolyPeptide Group (Switzerland) Performance
| PPGN Stock | CHF 27.95 0.40 1.41% |
The company holds a Beta of 0.33, which implies possible diversification benefits within a given portfolio. As returns on the market increase, PolyPeptide Group's returns are expected to increase less than the market. However, during the bear market, the loss of holding PolyPeptide Group is expected to be smaller as well. At this point, PolyPeptide Group has a negative expected return of -0.2%. Please make sure to check PolyPeptide Group's value at risk, skewness, and the relationship between the maximum drawdown and potential upside , to decide if PolyPeptide Group performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PolyPeptide Group AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 17.2 M | |
| Total Cashflows From Investing Activities | -80.8 M |
PolyPeptide |
PolyPeptide Group Relative Risk vs. Return Landscape
If you would invest 3,260 in PolyPeptide Group AG on September 12, 2024 and sell it today you would lose (465.00) from holding PolyPeptide Group AG or give up 14.26% of portfolio value over 90 days. PolyPeptide Group AG is generating negative expected returns and assumes 2.5534% volatility on return distribution over the 90 days horizon. Simply put, 22% of stocks are less volatile than PolyPeptide, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
PolyPeptide Group Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PolyPeptide Group's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PolyPeptide Group AG, and traders can use it to determine the average amount a PolyPeptide Group's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0802
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PPGN |
Estimated Market Risk
| 2.55 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PolyPeptide Group is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PolyPeptide Group by adding PolyPeptide Group to a well-diversified portfolio.
PolyPeptide Group Fundamentals Growth
PolyPeptide Stock prices reflect investors' perceptions of the future prospects and financial health of PolyPeptide Group, and PolyPeptide Group fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PolyPeptide Stock performance.
| Return On Equity | 0.0809 | |||
| Return On Asset | 0.0467 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 755.81 M | |||
| Shares Outstanding | 33.12 M | |||
| Price To Book | 1.90 X | |||
| Price To Sales | 2.82 X | |||
| Revenue | 282.13 M | |||
| EBITDA | 83.35 M | |||
| Cash And Equivalents | 136.3 M | |||
| Cash Per Share | 5.67 X | |||
| Total Debt | 14.95 M | |||
| Debt To Equity | 0.14 % | |||
| Book Value Per Share | 12.97 X | |||
| Cash Flow From Operations | 57.35 M | |||
| Earnings Per Share | 0.94 X | |||
| Total Asset | 595.04 M | |||
About PolyPeptide Group Performance
Evaluating PolyPeptide Group's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if PolyPeptide Group has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PolyPeptide Group has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. The company was founded in 1952 and is headquartered in Zug, Switzerland. POLYPEPTIDE is traded on Switzerland Exchange in Switzerland.Things to note about PolyPeptide Group performance evaluation
Checking the ongoing alerts about PolyPeptide Group for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PolyPeptide Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PolyPeptide Group generated a negative expected return over the last 90 days | |
| About 60.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing PolyPeptide Group's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PolyPeptide Group's stock is overvalued or undervalued compared to its peers.
- Examining PolyPeptide Group's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PolyPeptide Group's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PolyPeptide Group's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PolyPeptide Group's stock. These opinions can provide insight into PolyPeptide Group's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for PolyPeptide Stock Analysis
When running PolyPeptide Group's price analysis, check to measure PolyPeptide Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPeptide Group is operating at the current time. Most of PolyPeptide Group's value examination focuses on studying past and present price action to predict the probability of PolyPeptide Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPeptide Group's price. Additionally, you may evaluate how the addition of PolyPeptide Group to your portfolios can decrease your overall portfolio volatility.